{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:07:22Z","timestamp":1776323242604,"version":"3.50.1"},"reference-count":87,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2014.0425","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:19:26Z","timestamp":1525252766000},"source":"Crossref","is-referenced-by-count":5,"title":["Treatment Resistant Hypertension"],"prefix":"10.3238","author":[{"given":"Franz","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Anlauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2014,6,20]]},"reference":[{"key":"10.3238\/arztebl.2014.0425_ref1","doi-asserted-by":"crossref","unstructured":"Krum H, Schlaich M, Whitbourn R, et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275\u201381.","DOI":"10.1016\/S0140-6736(09)60566-3"},{"key":"10.3238\/arztebl.2014.0425_ref2","doi-asserted-by":"crossref","unstructured":"Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M: Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903\u20139.","DOI":"10.1016\/S0140-6736(10)62039-9"},{"key":"10.3238\/arztebl.2014.0425_ref3","doi-asserted-by":"crossref","unstructured":"Scheffers IJ, Kroon AA, Schmidli J, et al.: Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010; 56: 1254\u20138.","DOI":"10.1016\/j.jacc.2010.03.089"},{"key":"10.3238\/arztebl.2014.0425_ref4","doi-asserted-by":"crossref","unstructured":"Bisognano JD, Bakris G, Nadim MK, et al.: Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58: 765\u201373.","DOI":"10.1016\/j.jacc.2011.06.008"},{"key":"10.3238\/arztebl.2014.0425_ref5","doi-asserted-by":"crossref","unstructured":"Calhoun DA, Jones D, Textor S, et al.: Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403\u201319.","DOI":"10.1161\/HYPERTENSIONAHA.108.189141"},{"key":"10.3238\/arztebl.2014.0425_ref6","doi-asserted-by":"crossref","unstructured":"Mancia G, Fagard R, Narkiewicz K, et al.: 2013 ESH\/ESC Guidelines for the management of arterial hypertension: TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281\u2013357.","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"10.3238\/arztebl.2014.0425_ref7","doi-asserted-by":"crossref","unstructured":"Rios MT, Dominguez-Sardina M, Ayala DE, et al.: Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Chronobiol Int 2013; 30: 207\u201320.","DOI":"10.3109\/07420528.2012.701135"},{"key":"10.3238\/arztebl.2014.0425_ref8","doi-asserted-by":"crossref","unstructured":"Pimenta E, Calhoun DA: Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012; 125: 1594\u20136.","DOI":"10.1161\/CIRCULATIONAHA.112.097345"},{"key":"10.3238\/arztebl.2014.0425_ref9","doi-asserted-by":"crossref","unstructured":"L\u00f6wel H, Meisinger C, Heier M, Hymer H, Alte D, V\u00f6lzke H: Epidemiologie der arteriellen Hypertonie in Deutschland. Ausgew\u00e4hlte Ergebnisse bev\u00f6lkerungsrepr\u00e4sentativer Querschnittstudien. Dtsch med Wochenschr 2006; 131: 2586\u201391.","DOI":"10.1055\/s-2006-956253"},{"key":"10.3238\/arztebl.2014.0425_ref10","doi-asserted-by":"crossref","unstructured":"Daugherty SL, Powers JD, Magid DJ, et al.: Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635\u201342.","DOI":"10.1161\/CIRCULATIONAHA.111.068064"},{"key":"10.3238\/arztebl.2014.0425_ref11","doi-asserted-by":"crossref","unstructured":"Pierdomenico SD, Lapenna D, Bucci A, et al.: Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18: 1422\u20138.","DOI":"10.1016\/j.amjhyper.2005.05.014"},{"key":"10.3238\/arztebl.2014.0425_ref12","doi-asserted-by":"crossref","unstructured":"de la Sierra A, Segura J, Banegas JR, et al.: Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 898\u2013902.","DOI":"10.1161\/HYPERTENSIONAHA.110.168948"},{"key":"10.3238\/arztebl.2014.0425_ref13","doi-asserted-by":"crossref","unstructured":"Kumbhani DJ, Steg PG, Cannon CP, et al.: Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013; 34: 1204\u201314.","DOI":"10.1093\/eurheartj\/ehs368"},{"key":"10.3238\/arztebl.2014.0425_ref14","doi-asserted-by":"crossref","unstructured":"Matthes J, Albus C: Improving adherence with medication\u2014a selective literature review based on the example of hypertension treatment. Dtsch Arztebl Int 2014; 111: 41\u20137.","DOI":"10.3238\/arztebl.2014.0041"},{"key":"10.3238\/arztebl.2014.0425_ref15","doi-asserted-by":"crossref","unstructured":"Daugherty SL, Powers JD, Magid DJ, et al.: The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension. Hypertension 2012; 60: 303\u20139.","DOI":"10.1161\/HYPERTENSIONAHA.112.192096"},{"key":"10.3238\/arztebl.2014.0425_ref16","doi-asserted-by":"crossref","unstructured":"Grassi G, Bombelli M, Seravalle G, Brambilla G, Dell\u2019oro R, Mancia G: Role of ambulatory blood pressure monitoring in resistant hypertension. Curr Hypertens Rep 2013; 15: 232\u20137.","DOI":"10.1007\/s11906-013-0349-0"},{"key":"10.3238\/arztebl.2014.0425_ref17","doi-asserted-by":"crossref","unstructured":"Ayala DE, Hermida RC, Mojon A, Fernandez JR: Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. Chronobiol Int 2013; 30: 340\u201352.","DOI":"10.3109\/07420528.2012.701455"},{"key":"10.3238\/arztebl.2014.0425_ref18","doi-asserted-by":"crossref","unstructured":"Douma S, Petidis K, Doumas M, et al.: Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921\u20136.","DOI":"10.1016\/S0140-6736(08)60834-X"},{"key":"10.3238\/arztebl.2014.0425_ref19","doi-asserted-by":"crossref","unstructured":"Acelajado MC, Pisoni R, Dudenbostel T, et al.: Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14: 7\u201312.","DOI":"10.1111\/j.1751-7176.2011.00556.x"},{"key":"10.3238\/arztebl.2014.0425_ref20","doi-asserted-by":"crossref","unstructured":"Sartori M, Calo LA, Mascagna V, et al.: Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 2006; 19: 373\u20139; discussion 380.","DOI":"10.1016\/j.amjhyper.2005.06.031"},{"key":"10.3238\/arztebl.2014.0425_ref21","doi-asserted-by":"crossref","unstructured":"Lozano L, Tovar JL, Sampol G, et al.: Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. J Hypertens 2010; 28: 2161\u20138.","DOI":"10.1097\/HJH.0b013e32833b9c63"},{"key":"10.3238\/arztebl.2014.0425_ref22","doi-asserted-by":"crossref","unstructured":"Faselis C, Doumas M, Papademetriou V: Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011: Article ID 236239, Doi: 10.4061\/2011\/236239.","DOI":"10.4061\/2011\/236239"},{"key":"10.3238\/arztebl.2014.0425_ref23","doi-asserted-by":"crossref","unstructured":"Brown MJ: Personalised medicine for hypertension. BMJ 2011; 343: d4697.","DOI":"10.1136\/bmj.d4697"},{"key":"10.3238\/arztebl.2014.0425_ref24","doi-asserted-by":"crossref","unstructured":"Mann SJ: Drug therapy for resistant hypertension: a simplified, mechanistic approach. J Clin Hypertens (Greenwich) 2011; 13: 120\u201330.","DOI":"10.1111\/j.1751-7176.2010.00387.x"},{"key":"10.3238\/arztebl.2014.0425_ref25","doi-asserted-by":"crossref","unstructured":"Mann SJ, Parikh NS: A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study. J Clin Hypertens (Greenwich) 2012; 14: 191\u20137.","DOI":"10.1111\/j.1751-7176.2012.00605.x"},{"key":"10.3238\/arztebl.2014.0425_ref26","doi-asserted-by":"crossref","unstructured":"Sica DA: Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin Hypertens (Greenwich) 2004; 6: 283\u20137.","DOI":"10.1111\/j.1524-6175.2004.03585.x"},{"key":"10.3238\/arztebl.2014.0425_ref27","doi-asserted-by":"crossref","unstructured":"Messerli FH, Bangalore S: Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. Am J Med 2011; 124: 896\u20139.","DOI":"10.1016\/j.amjmed.2011.05.009"},{"key":"10.3238\/arztebl.2014.0425_ref28","doi-asserted-by":"crossref","unstructured":"Viera AJ: Resistant hypertension. J Am Board Fam Med 2012; 25: 487\u201395.","DOI":"10.3122\/jabfm.2012.04.110275"},{"key":"10.3238\/arztebl.2014.0425_ref29","doi-asserted-by":"crossref","unstructured":"Roush GC, Holford TR, Guddati AK: Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012; 59: 1110\u20137.","DOI":"10.1161\/HYPERTENSIONAHA.112.191106"},{"key":"10.3238\/arztebl.2014.0425_ref30","doi-asserted-by":"crossref","unstructured":"Fong MW, Filippone JD, Beck GR, Katz MG, Bisognano JD: Improving care in resistant hypertension: medication trends and nonpharmacologic strategies in a specialty clinic. Am J Cardiovasc Drugs 2007; 7: 449\u201352.","DOI":"10.2165\/00129784-200707060-00008"},{"key":"10.3238\/arztebl.2014.0425_ref31","doi-asserted-by":"crossref","unstructured":"Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV: Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension 2011; 58: 1008\u201313.","DOI":"10.1161\/HYPERTENSIONAHA.111.180497"},{"key":"10.3238\/arztebl.2014.0425_ref32","doi-asserted-by":"crossref","unstructured":"Sica DA: Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 2007; 9: 399\u2013405.","DOI":"10.1111\/j.1524-6175.2007.07161.x"},{"key":"10.3238\/arztebl.2014.0425_ref33","doi-asserted-by":"crossref","unstructured":"Mahfoud F, Himmel F, Ukena C, Schunkert H, B\u00f6hm M, Weil J: Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int 2011; 108: 725\u201331.","DOI":"10.3238\/arztebl.2011.0725"},{"key":"10.3238\/arztebl.2014.0425_ref34","doi-asserted-by":"crossref","unstructured":"Fadl Elmula FE, Hoffmann P, Fossum E, et al.: Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013; 62: 526\u201332.","DOI":"10.1161\/HYPERTENSIONAHA.113.01452"},{"key":"10.3238\/arztebl.2014.0425_ref35","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW, et al.: A Controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; This article was published on March 29, 2014. DOI: 10.1056\/NEJMoal402670.","DOI":"10.1016\/j.jvs.2014.05.038"},{"key":"10.3238\/arztebl.2014.0425_ref36","doi-asserted-by":"crossref","unstructured":"Schmieder RE, Redon J, Grassi G, et al.: ESH position paper: renal denervation\u2014an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837\u201341.","DOI":"10.1097\/HJH.0b013e328352ce78"},{"key":"10.3238\/arztebl.2014.0425_ref37","doi-asserted-by":"crossref","unstructured":"Froeschl M, Hadziomerovic A, Ruzicka M: Renal sympathetic denervation for resistant hypertension. Can J Cardiol 2013; 29: 636\u20138.","DOI":"10.1016\/j.cjca.2013.02.019"},{"key":"10.3238\/arztebl.2014.0425_ref38","doi-asserted-by":"crossref","unstructured":"Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M: Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. J Am Coll Cardiol 2012; 60: 2422\u20134.","DOI":"10.1016\/j.jacc.2012.08.1002"},{"key":"10.3238\/arztebl.2014.0425_ref39","unstructured":"Pleiner J: Die sekund\u00e4re Hypertonie als unerw\u00fcnschter Therapieeffekt. J Hypertonie 2002; 6: 55\u20136."},{"key":"10.3238\/arztebl.2014.0425_ref40","doi-asserted-by":"crossref","unstructured":"Grossman E, Messerli FH: Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125: 14\u201322.","DOI":"10.1016\/j.amjmed.2011.05.024"},{"key":"10.3238\/arztebl.2014.0425_ref41","doi-asserted-by":"crossref","unstructured":"Swales JD, Bing RF, Heagerty A, Pohl JE, Russell GI, Thurston H: Treatment of refractory hypertension. Lancet 1982; 1: 894\u20136.","DOI":"10.1016\/S0140-6736(82)92162-6"},{"key":"10.3238\/arztebl.2014.0425_ref42","doi-asserted-by":"crossref","unstructured":"Mancia G, De Backer G, Dominiczak A, et al.: Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105\u201387.","DOI":"10.1097\/HJH.0b013e3281fc975a"},{"key":"10.3238\/arztebl.2014.0425_ref43","doi-asserted-by":"crossref","unstructured":"Isaksson H, Ostergren J: Prognosis in therapy-resistant hypertension. J Intern Med 1994; 236: 643\u20139.","DOI":"10.1111\/j.1365-2796.1994.tb00857.x"},{"key":"10.3238\/arztebl.2014.0425_ref44","doi-asserted-by":"crossref","unstructured":"McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH: Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Ther 2009; 31: 1116\u201323.","DOI":"10.1016\/j.clinthera.2009.05.007"},{"key":"10.3238\/arztebl.2014.0425_ref45","doi-asserted-by":"crossref","unstructured":"Limonta LB, Valandro Ldos S, Shiraishi FG, Barretti P, Franco RJ, Martin LC: Causes of resistant hypertension detected by a standardized algorithm. Int J Hypertens 2012: Article ID 392657, doi:10.1155\/2012\/392657.","DOI":"10.1155\/2012\/392657"},{"key":"10.3238\/arztebl.2014.0425_ref46","doi-asserted-by":"crossref","unstructured":"Catena C, Colussi G, Nadalini E, et al.: Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80\u20135.","DOI":"10.1001\/archinternmed.2007.33"},{"key":"10.3238\/arztebl.2014.0425_ref47","doi-asserted-by":"crossref","unstructured":"Brown MA, Buddle ML, Martin A: Is resistant hypertension really resistant? Am J Hypertens 2001; 14: 1263\u20139.","DOI":"10.1016\/S0895-7061(01)02193-8"},{"key":"10.3238\/arztebl.2014.0425_ref48","doi-asserted-by":"crossref","unstructured":"Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M: Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 2011; 34: 87\u201390.","DOI":"10.1038\/hr.2010.183"},{"key":"10.3238\/arztebl.2014.0425_ref49","doi-asserted-by":"crossref","unstructured":"Mejia AD, Egan BM, Schork NJ, Zweifler AJ: Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension. Ann Intern Med 1990; 112: 270\u20137.","DOI":"10.7326\/0003-4819-112-4-270"},{"key":"10.3238\/arztebl.2014.0425_ref50","doi-asserted-by":"crossref","unstructured":"Pimenta E, Gaddam KK, Oparil S, et al.: Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54: 475\u201381.","DOI":"10.1161\/HYPERTENSIONAHA.109.131235"},{"key":"10.3238\/arztebl.2014.0425_ref51","unstructured":"National Clinical Guideline Centre: (commissioned by the National Institute for Health and Clinical Excellence) Hypertension. Clinical management of primary hypertension in adults. Clinical Guideline 127. http:\/\/publications.nice.org.uk\/hypertension-cg127 . issued: August 2011 (last accessed on 4 April 2014)."},{"key":"10.3238\/arztebl.2014.0425_ref52","doi-asserted-by":"crossref","unstructured":"Karns AD, Bral JM, Hartman D, Peppard T, Schumacher C: Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension. J Clin Hypertens (Greenwich) 2013; 15: 186\u201392.","DOI":"10.1111\/jch.12051"},{"key":"10.3238\/arztebl.2014.0425_ref53","doi-asserted-by":"crossref","unstructured":"Hood SJ, Taylor KP, Ashby MJ, Brown MJ: The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007; 116: 268\u201375.","DOI":"10.1161\/CIRCULATIONAHA.107.690396"},{"key":"10.3238\/arztebl.2014.0425_ref54","doi-asserted-by":"crossref","unstructured":"Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B: Resistant hypertension. Bmj 2012; 345: e7473.","DOI":"10.1136\/bmj.e7473"},{"key":"10.3238\/arztebl.2014.0425_ref55","doi-asserted-by":"crossref","unstructured":"Dernaika TA, Kinasewitz GT, Tawk MM: Effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea. J Clin Sleep Med 2009; 5: 103\u20137.","DOI":"10.5664\/jcsm.27435"},{"key":"10.3238\/arztebl.2014.0425_ref56","doi-asserted-by":"crossref","unstructured":"Baumgartner I, Lerman LO: Renovascular hypertension: screening and modern management. Eur Heart J 2011; 32: 1590\u20138.","DOI":"10.1093\/eurheartj\/ehq510"},{"key":"10.3238\/arztebl.2014.0425_ref57","doi-asserted-by":"crossref","unstructured":"Lenders JW, Eisenhofer G, Mannelli M, Pacak K: Phaeochromocytoma. Lancet 2005; 366: 665\u201375.","DOI":"10.1016\/S0140-6736(05)67139-5"},{"key":"10.3238\/arztebl.2014.0425_ref58","doi-asserted-by":"crossref","unstructured":"Brown MJ, Cruickshank JK, Dominiczak AF, et al.: Better blood pressure control: how to combine drugs. J Hum Hypertens 2003; 17: 81\u20136.","DOI":"10.1038\/sj.jhh.1001511"},{"key":"10.3238\/arztebl.2014.0425_ref59","doi-asserted-by":"crossref","unstructured":"Lindholm LH, Carlberg B, Samuelsson O: Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545\u201353.","DOI":"10.1016\/S0140-6736(05)67573-3"},{"key":"10.3238\/arztebl.2014.0425_ref60","doi-asserted-by":"crossref","unstructured":"Brown MJ: Heterogeneity of blood pressure response to therapy. Am J Hypertens 2010; 23: 926\u20138.","DOI":"10.1038\/ajh.2010.139"},{"key":"10.3238\/arztebl.2014.0425_ref61","doi-asserted-by":"crossref","unstructured":"Egan BM, Basile JN, Rehman SU, et al.: Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009; 22: 792\u2013801.","DOI":"10.1038\/ajh.2009.63"},{"key":"10.3238\/arztebl.2014.0425_ref62","doi-asserted-by":"crossref","unstructured":"Blumenfeld JD, Laragh JH: Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998; 11: 894\u20136.","DOI":"10.1016\/S0895-7061(98)00080-6"},{"key":"10.3238\/arztebl.2014.0425_ref63","doi-asserted-by":"crossref","unstructured":"Kincaid-Smith PS: The treatment of resistant hypertension. Drugs 1976; 11: 78\u201386.","DOI":"10.2165\/00003495-197600111-00020"},{"key":"10.3238\/arztebl.2014.0425_ref64","unstructured":"Nawar T, Nolin L, Plante GE, Caron C, Montambault P: Long-term treatment of severe hypertension with minoxidil. Can Med Assoc J 1977; 117: 1178\u201382."},{"key":"10.3238\/arztebl.2014.0425_ref65","doi-asserted-by":"crossref","unstructured":"Pettinger W: Introduction: the Brook Lodge conference on minoxidil. J Cardiovasc Pharmacol 1980; 2 : 91\u20132.","DOI":"10.1097\/00005344-198000022-00001"},{"key":"10.3238\/arztebl.2014.0425_ref66","doi-asserted-by":"crossref","unstructured":"Zacest R, Frewin DB, Robinson MA, et al.: Clinical and haemodynamic effects of minoxidil in refractory hypertension. Drugs 1976; 11: 177\u201384.","DOI":"10.2165\/00003495-197600111-00036"},{"key":"10.3238\/arztebl.2014.0425_ref67","doi-asserted-by":"crossref","unstructured":"Martin WB, Spodick DH, Zins GR: Pericardial disorders occurring during open-label study of 1,869 severely hypertensive patients treated with minoxidil. J Cardiovasc Pharmacol 1980; 2: 217\u201327.","DOI":"10.1097\/00005344-198000022-00016"},{"key":"10.3238\/arztebl.2014.0425_ref68","doi-asserted-by":"crossref","unstructured":"Taler SJ, Textor SC, Augustine JE: Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39: 982\u20138.","DOI":"10.1161\/01.HYP.0000016176.16042.2F"},{"key":"10.3238\/arztebl.2014.0425_ref69","doi-asserted-by":"crossref","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981\u201397 [Erratum, JAMA 2003; 289: 178].","DOI":"10.1001\/jama.288.23.2981"},{"key":"10.3238\/arztebl.2014.0425_ref70","doi-asserted-by":"crossref","unstructured":"Ritchie LD, Campbell NC, Murchie P: New NICE guidelines for hypertension. Bmj 2011; 343: d5644.","DOI":"10.1136\/bmj.d5644"},{"key":"10.3238\/arztebl.2014.0425_ref71","doi-asserted-by":"crossref","unstructured":"Bobrie G, Frank M, Azizi M, et al.: Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30: 1656\u201364.","DOI":"10.1097\/HJH.0b013e3283551e98"},{"key":"10.3238\/arztebl.2014.0425_ref72","doi-asserted-by":"crossref","unstructured":"Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB: Hypokalemia associated with diuretic use and cardiovascular events in the systolic hypertension in the elderly program. Hypertension 2000; 35: 1025\u201330.","DOI":"10.1161\/01.HYP.35.5.1025"},{"key":"10.3238\/arztebl.2014.0425_ref73","doi-asserted-by":"crossref","unstructured":"Raftos J: The difficult hypertensive. Drugs 1976; 11: 55\u201360.","DOI":"10.2165\/00003495-197611010-00005"},{"key":"10.3238\/arztebl.2014.0425_ref74","unstructured":"Liberman T: Clinical evaluation of the hypotensive drug catapresan. Kardiologiia 1977; 17: 113\u20137."},{"key":"10.3238\/arztebl.2014.0425_ref75","doi-asserted-by":"crossref","unstructured":"Falkner B, Onesti G, Lowenthal DT, Affrime MB: The use of clonidine monotherapy in adolescent hypertension. Chest 1983; 83: 425\u20137.","DOI":"10.1378\/chest.83.2.425"},{"key":"10.3238\/arztebl.2014.0425_ref76","unstructured":"Semenova RI, Musina NS: Experience with ebrantil used in patients with resistant arterial hypertension in chronic kidney disease. Ter Arkh 2012; 84: 72\u20134."},{"key":"10.3238\/arztebl.2014.0425_ref77","doi-asserted-by":"crossref","unstructured":"Persu A, Renkin J, Thijs L, Staessen JA: Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012; 60: 596\u2013606.","DOI":"10.1161\/HYPERTENSIONAHA.112.195263"},{"key":"10.3238\/arztebl.2014.0425_ref78","doi-asserted-by":"crossref","unstructured":"Kandzari DE, Bhatt DL, Sobotka PA, et al.: Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35: 528\u201335.","DOI":"10.1002\/clc.22008"},{"key":"10.3238\/arztebl.2014.0425_ref79","unstructured":"Medtronic press release 2014: http:\/\/newsroom.medtronic.com\/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=1889335& highlight= (last accessed on 4. April 2014)."},{"key":"10.3238\/arztebl.2014.0425_ref80","doi-asserted-by":"crossref","unstructured":"Pathak A, Girerd X, Azizi M, et al.: Expert consensus: renal denervation for the treatment of arterial hypertension. Arch Cardiovasc Dis 2012; 105: 386\u201393.","DOI":"10.1016\/j.acvd.2012.03.005"},{"key":"10.3238\/arztebl.2014.0425_ref81","doi-asserted-by":"crossref","unstructured":"Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD: Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012; 6: 152\u20138.","DOI":"10.1016\/j.jash.2012.01.003"},{"key":"10.3238\/arztebl.2014.0425_ref82","doi-asserted-by":"crossref","unstructured":"Alnima T, de Leeuw PW, Tan FE, Kroon AA: Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension. Hypertension 2013; 61: 1334\u20139.","DOI":"10.1161\/HYPERTENSIONAHA.113.01159"},{"key":"10.3238\/arztebl.2014.0425_ref83","doi-asserted-by":"crossref","unstructured":"Doumas M, Faselis C, Tsioufis C, Papademetriou V: Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure. Curr Hypertens Rep 2012; 14: 238\u201346.","DOI":"10.1007\/s11906-012-0258-7"},{"key":"10.3238\/arztebl.2014.0425_ref84","doi-asserted-by":"crossref","unstructured":"Hoppe UC, Brandt MC, Wachter R, et al.: Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012; 6: 270\u20136.","DOI":"10.1016\/j.jash.2012.04.004"},{"key":"10.3238\/arztebl.2014.0425_ref85","doi-asserted-by":"crossref","unstructured":"Gassler JP, Lynch PS, Bisognano JD: The role of baroreflex activation therapy in sympathetic modulation for the treatment of resistant hypertension. Heart 2012; 98: 1689\u201392.","DOI":"10.1136\/heartjnl-2012-302366"},{"key":"10.3238\/arztebl.2014.0425_ref86","doi-asserted-by":"crossref","unstructured":"Menne J, Jordan J, Linnenweber-Held S, Haller H: Resistant hypertension: baroreflex stimulation as a new tool. Nephrol Dial Transplant 2013; 28: 288\u201395.","DOI":"10.1093\/ndt\/gfs504"},{"key":"10.3238\/arztebl.2014.0425_ref87","doi-asserted-by":"crossref","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206\u201352.","DOI":"10.1161\/01.HYP.0000107251.49515.c2"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2014.0425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:36:40Z","timestamp":1638797800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2014.0425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,20]]},"references-count":87,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2014.0425","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,20]]}}}